Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating
Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating
坎托·菲茨杰拉德将Ultragenyx Pharmaceutical的目标股价从107美元调整至115美元，维持增持评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册